Amivantamab and Hyaluronidase-lpuj
This page contains brief information about amivantamab and hyaluronidase-lpuj and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Amivantamab and hyaluronidase-lpuj is approved to treat adults with:
- non-small cell lung cancer that has an abnormal EGFR gene and has spread. It is used:
- with lazertinib mesylate hydrate as the first treatment
- with carboplatin and pemetrexed disodium in patients whose cancer got worse during or after treatment with an EGFR tyrosine kinase inhibitor
- with carboplatin and pemetrexed disodium as the first treatment
- alone in patients whose cancer got worse during or after platinum chemotherapy
For information about amivantamab-vmjw that may apply to amivantamab and hyaluronidase-lpuj, see the Drug Information Summary for Amivantamab-vmjw.
Amivantamab and hyaluronidase-lpuj is also being studied in the treatment of other types of cancer.
More About Amivantamab and Hyaluronidase-lpuj
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Amivantamab and Hyaluronidase-lpuj - Check for trials from NCI's list of cancer clinical trials now accepting patients.